At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Nivolumab/Ipilimumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Stereotactic Body Radiation Therapy in Combination With Nivolumab Plus Ipilimumab in Patients With Metastatic Renal Cell Cancer
University of Texas Southwestern Medical Center·interventional·Posted Feb 27, 2017·Updated Mar 30, 2021
In Brief
A Phase 2 clinical trial evaluating Nivolumab/Ipilimumab and SBRT for Kidney Cancer Metastatic and 2 related conditions. Completed, enrolled 29 participants across 2 sites.
Detailed Summary
This is a multi-institution, single-arm phase II study to determine the safety and efficacy of SBRT (up to 2 metastatic sites preferentially lung, mediastinum or bone in combination of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma(with a clear-cell component and at least 1 measurable metastatic lesion that is not being irradiated).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedFeb 2017
Enrollment StartMar 2017
Primary CompletionFeb 2020
Study CompletionNov 2020
TodayJul 2026
First PostedFeb 27, 2017
Enrollment StartMar 1, 2017
Primary CompletionFeb 20, 2020
Study CompletionNov 17, 2020
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 9.3 years ago
Interventions
Nivolumab/Ipilimumabdrug
IV immunotherapy
SBRTradiation
SBRT will be delivered in conjunction with immunotherapy